

8 January 2007



**National Institute for  
Health and Clinical Excellence**

MidCity Place  
71 High Holborn  
London  
WC1V 6NA

Tel: +44 (0)20 7067 5800

Fax: +44 (0)20 7067 5801

nice@nice.org.uk

[www.nice.org.uk](http://www.nice.org.uk)

Dear Consultee/Commentator

**Health Technology Appraisal**

**Atrasentan for the treatment of hormone-refractory prostate cancer**

As you maybe aware, the Department of Health and the Welsh Assembly Government asked the Institute to conduct an appraisal of atrasentan for prostate cancer, and to provide guidance on its use to the NHS in England and Wales.

The manufacturer of atrasentan has advised us that they have not applied for EMEA regulatory approval in relation to this product at this time. The Institute has therefore decided to remove this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (☎ 020 7067 5896 or email: [Cathryn.hall@nice.org.uk](mailto:Cathryn.hall@nice.org.uk)).

Yours sincerely

Dr Carole Longson  
Director of Centre for Health Technology Evaluation